Iva Mucalo
Overview
Explore the profile of Iva Mucalo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
250
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Prue G, Czamanski-Cohen J, Kassianos A, Pilleron S, Ladas A, Akcakaya Can A, et al.
BMJ Open
. 2025 Feb;
15(2):e085456.
PMID: 39956597
Introduction: Cancer and its treatments can lead to a wide range of side-effects that can persist long after treatments have ended. Across Europe, survivorship care is traditionally hospital-based specialist-led follow-up,...
2.
Hosszu D, Dima A, Fernandez F, Schneider M, van Dijk L, Toth K, et al.
Expert Rev Pharmacoecon Outcomes Res
. 2024 Jun;
24(7):853-860.
PMID: 38934097
Background: This study aims to create a comprehensive framework for the development and implementation of digital medication adherence technologies (DMATech), focusing on critical stages where engagement of medication users (MU)...
3.
Okrosa A, Silovski T, Dedic Plavetic N, Silovski H, Kovacic A, Mucalo I
Acta Pharm
. 2023 Dec;
73(4):673-689.
PMID: 38147479
This observational, cross-sectional study conducted at the University Hospital Centre Zagreb (UHC Zagreb) aimed to explore patients' beliefs about adjuvant endocrine therapy (AET) as well as their association with non-adherence...
4.
Brajkovic A, Bicanic L, Orehovacki H, Prkacin I, Oliveira D, Mucalo I
Acta Pharm
. 2023 Dec;
73(4):723-734.
PMID: 38147475
This perspective, pre- and post-intervention study with a one-year follow-up primarily aimed to ascertain prescribers' approval rate of pharmacists' interventions and clinical status of hypertension following comprehensive medication management (CMM)...
5.
Mirosevic Skvrce N, Omrcen L, Pavicic M, Mucalo I
Res Social Adm Pharm
. 2023 Nov;
20(2):99-104.
PMID: 37923574
Background: Use of medicinal products in paediatric patients is identified as a risk factor for the occurrence of medication errors. Objectives: To describe and identify root causes of medication errors...
6.
Orehovacki H, Brajkovic A, Bicanic L, Mucalo I
Croat Med J
. 2023 Sep;
64(4):295-300.
PMID: 37654043
No abstract available.
7.
Lesnjakovic L, Ganoci L, Bilic I, Simicevic L, Mucalo I, Plestina S, et al.
Pharmacogenomics
. 2023 Jan;
24(2):93-106.
PMID: 36636997
Fluoropyrimidines (FPs) are antineoplastic drugs widely used in the treatment of various solid tumors. Nearly 30% of patients treated with FP chemotherapy experience severe FP-related toxicity, and in some cases,...
8.
Brajkovic A, Bicanic L, Strgacic M, Orehovacki H, Ramalho-de-Oliveira D, Mucalo I
Pharmacy (Basel)
. 2022 Sep;
10(5).
PMID: 36136835
The aim of this research was to assess the impact of comprehensive medication management (CMM) services on patients’ health-related quality of life (HRQoL) and frequency of adverse drug reactions (ADRs)...
9.
Fehir Sola K, Vladimir-Knezevic S, Hrabac P, Mucalo I, Saso L, Verbanac D
Eur J Clin Nutr
. 2022 Aug;
76(12):1675-1681.
PMID: 35927504
Background And Objectives: Constipation is one of the most common gastrointestinal conditions, particularly among older individuals. This study aimed to evaluate the efficacy and safety of selected multistrain probiotics on...
10.
Skelin M, Sarcevic D, Lesin Gacina D, Mucalo I, Dilber I, Javor E
J Chemother
. 2022 May;
35(2):150-157.
PMID: 35550005
BRCA1/2 mutations and homologous recombination deficiency (HRD) predispose to increased sensitivity to poly(ADP-ribose)polymerase (PARP) inhibitor treatment. Our aim was to evaluate the PARP inhibitors effect on progression free survival (PFS)...